New hope for lymphoma patients: experimental drug TORL-5-700 enters human trials

NCT ID NCT07439653

Recruiting now Disease control Sponsor: TORL Biotherapeutics, LLC Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a new drug called TORL-5-700, given alone or with other medicines, for people with B-cell Non-Hodgkin lymphoma that has come back or stopped responding to treatment. The goal is to find a safe dose and see if it can shrink tumors. About 155 adults will take part in this early-phase trial.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HISTOLOGICALLY CONFIRMED RELAPSED OR REFRACTORY B-CELL NON-HODGKIN LYMPHOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

B-cell neoplasm B-cell non-Hodgkin lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HISTOLOGICALLY CONFIRMED RELAPSED OR REFRACTORY B-CELL NON-HODGKIN LYMPHOMA

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Sarah Cannon Research Institute
RECRUITING

Nashville, Tennessee, 37203, United States
Stanford University
RECRUITING

Stanford, California, 94305, United States
UCLA
RECRUITING

Santa Monica, California, 90404, United States